TP53 and neoplasm: The KMT2A knockdown or pharmacological inhibition of KMT2A were sufficient to inhibit tumor progression, which indicates that KMT2A is essential for the cancer phenotype of cells containing GOF p53 mutants and for driving cancer growth.